Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw